Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Measures to Promote Development of Unapproved Drugs Proposed by Industry
October 5, 2009
- REGULATORY NEWS IN BRIEF
October 5, 2009
- SURVEY／60% of Doctors Voted for DPJ Because of Frustration with LDP
October 5, 2009
- Biomarker Science to Develop Alternative Therapy for Heart Transplantation
October 5, 2009
- METI to Support Drug Development Technology
September 28, 2009
- NEW PRODUCTS
September 28, 2009
- JPMA to Stress Importance of Pharma Industry to New Govt
September 28, 2009
- First Biosimilars Priced at 70% of Prices of Original Products
September 28, 2009
- REGULATORY NEWS IN BRIEF
September 28, 2009
- Sales of Ethical Drugs Up 5.3% in July: Crecon
September 28, 2009
- Akira Nagatsuma Appointed Health Minister
September 28, 2009
- Novo Nordisk to Develop Worlds First Oral GLP-1 Analogue, Insulin
September 28, 2009
- Galderma Aims at No. 1 Position in Dermatology
September 28, 2009
- Liraglutide Reduces HbA1c More Significantly Than Sitagliptin: Novo Nordisk
September 28, 2009
- Taisho to Acquire BMSs Indonesian Subsidiary
September 28, 2009
- WG to Conduct Clinical Trials to Determine Ethnic Differences among Asians
September 28, 2009
- Caduet to Target Patients Untreated for Hypertension or Hypercholesterolemia
September 28, 2009
- 9th Kitasato Harvard Symposium
September 28, 2009
- Deep Valley of Death Ahead of Japanese Bioventures: Mr Yoshida
September 28, 2009
- R&D CARE NEWS IN BRIEF
September 28, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…